RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKET PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.24+0.06 (+2.75%)
Close on Oct 19, 2026
- Market cap
- $256.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -63.3% | -34.5% | -60.3% | |
| Return on assets | -6.2% | -29.0% | -52.0% | |
| Current ratio | 18.23 | 14.94 | 6.38 | |
| Interest coverage | – | -19.3× | -122.6× | |
| Diluted shares | 7M | 55M | 111M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Rocket Pharmaceuticals generated $893.96M from operations and spent $38.72M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$893.96M
Used
$38.72M
Capital expenditure$38.72M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$223.12M
- Cash generatingOperating cash flow above zero-$190.01M
- Return on assets improvedROA up on the prior year-45.7% → -42.3%
- Earnings backed by cashOperating cash flow above net income-$190.01M vs -$223.12M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.30 → 6.38
- No dilutionShare count did not rise95M → 111M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00